Vivos Therapeutics, Inc. (VVOS) has completed its acquisition of The Sleep Center of Nevada - SCN, marking its first major step in directly operating sleep testing and treatment centers.
The deal aligns with Vivos' strategic shift from a dental provider-based model to direct patient care through medical sleep practice ownership.
The acquisition, valued at $9 million in cash and stock with potential earn-outs, brings SCN's seven-location, high-volume operation under Vivos' management. SCN serves around 3,000 new patients monthly and has diagnosed and treated over 200,000 sleep disorder cases. With SCN's 90 percent positive OSA diagnosis rate, Vivos plans to offer its FDA-cleared oral appliances as alternatives to CPAP and other legacy treatments.
Vivos expects higher-margin revenue from diagnostics, consulting, and appliance sales. Integration has already begun at two SCN locations, with full ramp-up anticipated over the next 12-18 months. Financing includes an $8.2 million senior loan from Streeterville Capital and a $3.75 million equity investment from New Seneca Partners.
Leadership from SCN, including Drs. Prabhu and Tara Rachakonda, has joined Vivos and expressed strong belief in the treatment. Investors also affirmed confidence in Vivos' scalable model, expecting reduced cash burn and improved cash flow.
VVOS is currently trading at $2.27, or 7.50% higher on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.